Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. (ARDS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ARDS · as of Sep 30, 2025
Ownership Breakdown
1
Institutional Holders
▲ 1 vs Q2
$3
Total Inst. Value
▲ $3 vs Q2
44.57M
Shares Outstanding
freeFloat 90.44%
3,000
13F Shares Held
▲ 3,000 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ARDS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 1 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
STRENGTHENING FAMILIES & COMMUNITIES, LLC pharmaceutical preparations | 3.0K | 0.80% | 0.80% | $3,000 | Nov 4, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
0
Increased
+0 shares1
New Positions
first time holders0
Decreased
−0 shares0
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
+1
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ARDS insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
5
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Windham-Bannister Susan Richards director | Jun 27, 2024 | Award | 200,000 | $0.06 | $12.6K | 261.0K | Form 4 ↗ |
HAMILTON JOHN F director | Jun 27, 2024 | Award | 200,000 | $0.06 | $12.6K | 269.0K | Form 4 ↗ |
Jafri Hasan Chief Medical Officer | Jun 27, 2024 | Award | 250,000 | $0.06 | $15.8K | 382.5K | Form 4 ↗ |
Patzer Eric director | Jun 24, 2024 | Purchase | 714,286 | $0.07 | $50.0K | 884.6K | Form 4 ↗ |
Truong Vu CEO | Jun 24, 2024 | Purchase | 714,286 | $0.07 | $50.0K | 1.38M | Form 4 ↗ |
HAMILTON JOHN F director | Sep 18, 2023 | Award | 15,000 | $0.08 | $1.2K | 91.5K | Form 4 ↗ |
Windham-Bannister Susan Richards director | Sep 18, 2023 | Award | 15,000 | $0.08 | $1.2K | 73.5K | Form 4 ↗ |
Patzer Eric Executive Chairman | Sep 18, 2023 | Award | 15,000 | $0.08 | $1.2K | 161.9K | Form 4 ↗ |
Truong Vu CEO and Director | Sep 18, 2023 | Award | 30,000 | $0.08 | $2.4K | 817.8K | Form 4 ↗ |
Jafri Hasan Chief Medical Officer | Sep 18, 2023 | Award | 20,000 | $0.08 | $1.6K | 175.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Aridis Pharmaceuticals, Inc. (ARDS) is primarily owned by institutional investors, who hold approximately 0.0% of total shares outstanding. Company insiders own approximately 9.56%, while retail and public investors account for the remaining 90.44%.
The largest institutional shareholder of Aridis Pharmaceuticals, Inc. is STRENGTHENING FAMILIES & COMMUNITIES, LLC, holding approximately 3,000 shares — equal to 0.80% of outstanding shares — as of September 30, 2025.
A total of 1 institutional investors currently hold ARDS stock, with a combined institutional value of approximately $3 as of the most recent 13F filing period.
Frequently asked questions
ARDS ownershipAridis Pharmaceuticals, Inc. (ARDS) is primarily owned by institutional investors, who hold approximately 0.0% of shares. The largest shareholder is STRENGTHENING FAMILIES & COMMUNITIES, LLC with a 0.80% stake. Company insiders hold 9.56%. Data sourced from SEC Form 13F as of September 30, 2025.